Related Experiment Video
Updated: Mar 26, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction
Angela K Shen1, Jonathan M Weiss2, Jon Kim Andrus3
1Angela K. Shen (angela.shen@hhs.gov) is a senior science policy adviser in the National Vaccine Program Office of the Department of Health and Human Services, in Washington, D.C. This work was performed when she was a senior adviser for vaccines and immunizations at the US Agency for International Development.
Abstract:
Since the mid-2000s low- and lower-middle-income countries have been focusing on developing and using evidence for immunization policy making, with an increasing emphasis on cost-effectiveness analysis, program costing, and financial flows-particularly for the introduction of newer, more expensive vaccines. While this is critical to informing decisions, countries still need to increase national immunization investment and explore innovative approaches to augment financing of immunization programs. The need for increased financing is especially strong in countries transitioning from support by Gavi, the Vaccine Alliance. With increased fiscal space to finance health and immunization programs as a result of improved economic performance, low- and lower-middle-income countries can reach the health status enjoyed by wealthier nations within a generation. However, new strategies and approaches related to domestic resources for immunization programs are needed to achieve this goal. Governments will need to increase their investments and modify existing external immunization financing arrangements if country ownership of immunization programs and the full promise of new vaccines are to be realized.
More Related Videos
Related Concept Videos
Vaccine Production
Vaccines
Vaccinations
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Control Governance: Regulatory Bodies and Their Impact

